IP Library Granted Patent US 12668578
Granted Patent B2
US 12668578 · App. 18/472,895 · Granted Jun 30, 2026

Furanic quaternary ammonium salts

Inventors: Konstantinos Goulas (Corvallis, OR); Truc Phung (Corvallis, OR)
Assignee: Oregon State University
C07D307/52B01J23/44C07D307/42C07D307/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12668578
App. No.
18/472,895
Granted
Jun 30, 2026
Kind
B2
Abstract

Disclosed herein is a method for making a quaternary ammonium salt according to the formula Also disclosed is a method for making the ammonium salts from an oleofuran compound. The compounds are useful as antibacterial and/or antiviral compounds and methods for administering the compounds also are disclosed.

Claims (59)

1 . A compound having a formula

wherein:

R 1 is optionally substituted C 6-20 alkyl;

each of R 2 , R 3 , and R 4 independently is H, C 1-6 alkyl, aldehyde, or OH;

R 5 is H or C 1-3 alkyl;

R 10 is optionally substituted C 2-20 aliphatic;

each of R 11 and R 12 independently is H or C 1-6 alkyl; and

X is halide or OH.

2 . The compound of claim 1 wherein R 1 , R 10 or both are independently substituted with one or more hydroxy, amine, or carbonyl moieties, or a combination thereof.

3 . The compound of claim 1 , wherein R 1 is C 6-18 alkyl.

4 . The compound of claim 1 , wherein R 10 is C 2-4 alkyl.

5 . The compound of claim 1 , wherein each of R 11 and R 12 independently is C 1-6 alkyl.

6 . The compound of claim 1 , wherein one or both of R 11 and R 12 is methyl.

7 . The compound of claim 1 , wherein each of R 2 , R 3 , and R 4 independently is H or C 1-6 alkyl.

8 . The compound of claim 1 , wherein R 2 , R 3 , and R 4 are all H.

9 . The compound of claim 1 , wherein X is Cl, Br, I or OH.

10 . The compound of claim 1 , wherein:

R 1 is C 6 alkyl;

R 10 is C 3 alkyl;

R 2 , R 3 , and R 4 are all H;

R 11 and R 12 are both methyl; and

X is Cl.

11 . A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable excipient.

12 . A method of making a compound according to claim 1 , the method comprising:

a) forming a mixture comprising a compound having a formula A-1

and a compound having a formula

to form a compound having a formula A-2

b) exposing the compound having formula A-2 to reducing conditions to form a compound having a formula A-3

c) treating the compound having the formula A-3 with a compound of formula R 11 X and a compound of formula R 12 X to form a compound having a formula A-4

wherein

R 1 is optionally substituted C 6-20 alkyl;

each of R 2 , R 3 , and R 4 independently is H, C 1-6 alkyl, aldehyde, or OH;

R 5 is H or C 1-3 alkyl;

R 10 is optionally substituted C 2-20 aliphatic;

each of R 11 and R 12 independently is H, or C 1-6 alkyl; and

each X independently is halide or OH.

13 . The method of claim 12 wherein exposing the compound having formula A-2 to reducing conditions comprises treating the compound with a reducing agent or hydrogen gas in the presence of a catalyst.

14 . The method of claim 13 , wherein:

the reducing agent is a borohydride reagent; or

the catalyst is a palladium-based catalyst.

15 . The method of claim 12 , wherein each X is Cl or Br.

16 . A method of making a compound according to claim 1 , the method comprising:

a) forming a mixture comprising a compound having a formula A-1

and a compound having a formula

and exposing the mixture to reducing conditions to form a compound having a formula A-5

and

b) treating the compound having the formula A-5 with a compound of formula R 12 X to form a compound having a formula A-6

wherein

R 1 is optionally substituted C 6-20 alkyl;

each of R 2 , R 3 , and R 4 independently is H, C 1-6 alkyl, aldehyde, or OH;

R 5 is H or C 1-3 alkyl;

R 10 is optionally substituted C 2-20 aliphatic;

each of R 11 and R 12 independently is H, or C 1-6 alkyl; and

each X independently is halide or OH.

17 . The method of claim 16 wherein exposing the mixture to reducing conditions comprises treating the compound with a reducing agent or hydrogen gas optionally in the presence of a catalyst.

18 . The method of claim 17 , wherein:

the reducing agent is a borohydride reagent; or

the catalyst is a palladium-based catalyst.

19 . The method of claim 16 , wherein each X is Cl or Br.